<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945200</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1003</org_study_id>
    <nct_id>NCT04945200</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer</brief_title>
  <official_title>Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer: Clinical Response and Biomarkers Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary object of this study is to determine tumor major pathological response (MPR) rate&#xD;
      and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer who&#xD;
      subjected to neoadjuvant immune checkpoint inhibitor combined with chemotherapy and molecular&#xD;
      biomarkers related to the clinical response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>molecular biomarkers related to clinical response</measure>
    <time_frame>change from baseline to postoperation, an average of 1 week</time_frame>
    <description>molecular biomarkers related to tumor major pathological response (MPR) and pathologic complete response (pCR) in stage IB-IIIA non-small cell lung cancer who subjected to neoadjuvant immune checkpoint inhibitor combined with chemotherapy</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        stage IB-IIIA NSCLC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.Able to understand the nature of this trial and provide written informed consent.&#xD;
&#xD;
        2.18 years ≤ age ≤ 80 years&#xD;
&#xD;
        3.Histologically documented non-small cell lung cancer&#xD;
&#xD;
        4.NSCLC with resection option for potential cure.This may include clinical stage IB, II and&#xD;
        IIIA.&#xD;
&#xD;
        5.Subjected to neoadjuvant immune checkpoint inhibitor combined with chemotherapy according&#xD;
        to disease evaluation.&#xD;
&#xD;
        6.Measurable disease by RECIST v1.1&#xD;
&#xD;
        7.Tumor tissue sample and/or alveolar lavage fluid must be available for biomarker&#xD;
        evaluation before operation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects are excluded if they are enrolled in any other interventional studies.&#xD;
&#xD;
          2. Administration of chemotherapy, device therapy or any other cancer therapy in 4 weeks&#xD;
             before the study drug administration.&#xD;
&#xD;
          3. Subjects are excluded if they have an active, known or suspected autoimmune disease&#xD;
             requiring systemic treatment (e.g.corticosteroids or other immunosuppressive&#xD;
             medications) in 2 years before the study drug administration. substitution therapy (&#xD;
             e.g. thyroxine, insulin) are permitted.&#xD;
&#xD;
          4. Subjects with active concurrent malignancies are excluded i.e. cancers other than&#xD;
             NSCLC.&#xD;
&#xD;
          5. History of allergy to study drug components&#xD;
&#xD;
          6. Any other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or may&#xD;
             interfere with the interpretation of study results.&#xD;
&#xD;
          7. Any other conditions that, in the Investigator's opinion, unfit to attend this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Pingli Wang, M.D</last_name>
    <phone>+86 135 1680 8409</phone>
    <email>pingliwang@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pingli Wang, M.D</last_name>
      <phone>+86 135 1680 8409</phone>
      <email>pingliwang@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-small cell lung cancer, neoadjuvant, biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

